KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Amortizatization of Intangibles (2016 - 2023)

Travere Therapeutics (TVTX) has disclosed Amortizatization of Intangibles for 12 consecutive years, with $2.3 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Amortizatization of Intangibles rose 122.39% year-over-year to $2.3 million, compared with a TTM value of $5.7 million through Dec 2023, up 717.43%, and an annual FY2025 reading of $4.4 million, down 2.18% over the prior year.
  • Amortizatization of Intangibles was $2.3 million for Q4 2023 at Travere Therapeutics, up from $1.9 million in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $2.3 million in Q4 2023 and bottomed at -$697000.0 in Q4 2021.
  • Average Amortizatization of Intangibles over 5 years is $161333.3, with a median of -$155500.0 recorded in 2020.
  • The sharpest move saw Amortizatization of Intangibles skyrocketed 295.1% in 2019, then tumbled 2022.22% in 2020.
  • Year by year, Amortizatization of Intangibles stood at $9000.0 in 2019, then crashed by 2022.22% to -$173000.0 in 2020, then tumbled by 302.89% to -$697000.0 in 2021, then surged by 246.77% to $1.0 million in 2022, then soared by 122.39% to $2.3 million in 2023.
  • Business Quant data shows Amortizatization of Intangibles for TVTX at $2.3 million in Q4 2023, $1.9 million in Q3 2023, and $1.0 million in Q4 2022.